Objective: The aim of this study was to examine Factor V G1691A (Leiden) (FVL) and prothrombin G20210A (PT) gene mutation status, and their relationship with thrombosis in patients with chronic myeloproliferative disorders (CMPDs). Materials and Methods: The study included 160 patients with a CMPD that were regularly followed-up between 1993 and 2009. FVL and PT mutation status was established based on blood samples analyzed via PCR using specific primers. Results: The frequency of FVL and PT mutation was 12.5% and 4.4%, respectively. In total, 27 episodes of thrombosis occurred in 24 (15%) of the patients, and there wasn't an association between the observed thrombotic events, and FVL or PT mutations. Hepatic vein thrombosis was noted in 3 patients that had FVL mutation, of which 1 also had PT mutation. Conclusion: We did not observe a relationship between thrombosis, and FVL or PT mutations in CMPD patients; however, 3 of the patients that had hepatic vein thrombosis also had FVL mutation. Larger studies are needed to more clearly determine if all CMPD patients with hepatic vein thrombosis need be investigated for FVL and PT mutation. (Turk J Hematol 2011; 28: 306-11) 
Introduction
Arterial and venous thrombosis are common causes of morbidity and mortality in patients with chronic myeloproliferative disorders (CMPDs). Generally, thrombotic events are more frequently reported than bleeding complications in patients with essential thrombocythemia (ET) and polycythemia vera (PV) at the time of diagnosis and during follow-up [1] . The frequency of thrombotic events in patients with idiopathic myelofibrosis (IMF) was reported to be 7.2%-11.6% [2, 3] .
Factor V G1691A (Leiden) (FVL) and prothrombin 20210A (PT) gene mutations are the most common genetic anomalies factors in patients with venous thromboembolism. The frequency of FVL ranges from 1.4% in Italy to 7% in Greece [4] . In the general Caucasian population the prevalence of the PT 20210A allele is 2% showing difference according to geographic variation approximately 2%, with some geographic variation [5] . The prevalence of FVL and PT mutation in Turkey was reported to be 7.4%-10.8% and 2.6%, respectively [6] [7] [8] [9] [10] , which differs from the reported incidence of FVL and PT mutation in patients with ET and PV [11] [12] [13] . To the best of our knowledge the frequency of FVL and PT mutation in patients with IMF has not been reported. Furthermore, the relationship between thrombophilic factors such as FVL and protrombine mutations thrombophilic factors and the occurrence of thrombosis in patients entering this study these patients remains unclear. As such, the present study aimed to determine the FVL and PT mutation status, and the relationship between these mutations and thrombosis in patients with CMPDs.
Materials and Methods
The study included 160 CMPD patients that were regularly follow-up at our hematology department between January 1993 and September 2009. Diagnosis of CMPDs was based on the criteria accepted at the time the patients presented (PSVSG 14 ). All patients were informed about the study and provided written informed consent, and the Ege University Local Ethics Committee approved the study protocol.
Blood samples (3 mL of peripheral blood) were collected into tubes containing EDTA) between February 2008 and September 2009. Patient data were collected at the time of sample collection based on the patient files, and included date of diagnosis, occurrence of arterial and venous thrombosis, symptoms, and complete blood count and other laboratory measurements at the time of diagnosis.
We used the blood samples to identify FVL G1691A and PT 20210A gene mutations. Genomic DNA was extracted from peripheral leukocytes using the High Pure PCR Template Preparation Kit (Roche Applied Science). In brief, 200 μL of DNA binding buffer (6 M guanidine-HCl, 10 mM urea, 10 mM Tris-HCl, and 20% Triton X-100 [pH 4.4]) and 40 μL of proteinase K were added to 200 μL of EDTAcontaining blood. The mixture containing proteinase K was incubated for 10 min at 72°C, and then 100 μL of isopropanol was added to the mixture samples, which were placed in filter tubes containing glass fiber (in order to bind DNA) and centrifuged at 8000 rpm. The DNA that bound to the filter tubes was washed twice with buffer (20 mM NaCl The presence of FVL G1691A and PT G20210A mutation was analyzed using commercially available Light Cycler FVL and PT mutation detection kits (Roche Applied Science). Wild type and mutated alleles were identified using the specific melting temperature (Tm) of the resulting amplicons. Tm values for FVL were 65°C for the wild type allele and 57°C for the G1691A allele, and for PT 60°C for the wild type allele and 49°C for the G20210A allele.
Statistical analysis
Statistical analysis of the data was performed with using SPSS v.12.0 for Windows (SPSS Inc, Chicago, III). Fisher's exact test was used to determine the significance of the difference between categorical variables (arterial and venous thrombosis, FVL and PT mutation, diagnostic subgroups). P values <0.05 were accepted as statistically significant.
Results
Among the 160 CMPD patients, 88 (55%) had ET, 48 (30%) had PV, 15 (9.3%) had IMF, and 9 (5.7%) had an unclassified CMPD. Median age of the patients (88 males and 77 females) was 59 years (range: 21-88 years). Patient characteristics are presented in Table 1 .
As at the time of presentation the patients' symptoms were quite varied, symptoms were classified based on systems. The patients' symptoms are shown in Table 2 .
In total, 27 episodes of thrombosis occurred in 24 (15%) of the 160 patients, and included 12 arterial and 15 venous episodes. Hepatic vein thrombosis was noted in 3 patients with FVL mutation, of which and 1 also had PT mutation. In all, 7 patients had portal vein thrombosis, none of which had FVL or PT mutation. respectively. All the observed mutations were heterozygous (Table 3 ). In total, 5 (21%) of the 24 patients with thrombosis had FVL mutation, of which 1 also had PT gene mutation. 
Discussion
Thrombotic events during the clinical course of CMPDs cause morbidity and mortality. Prevention of these events is among the primary goals of the treatment of CMPDs. In addition, hereditary thrombophilic factors are the most important cause of venous thrombosis. It remains unclear if there is a relationship between these factors and thrombotic events in CMPD. The present study examined the frequency of FVL and PT mutation in CMPD patients, as well as the relationship between FVL and PT mutation, and arterial and venous thrombotic events.
The frequency of thrombotic events in the patients with ET and PV (18.2% and 14.5%, respectively) was similar to that previously reported (11%-29.4% and 13%-38.6%, respectively) [1, 15] . In all, 2 (13.3%) thrombotic events occurred in 1 of the 15 patients with IMF in the present study. A retrospective study reported that 11 of 26 patients with IMF had arterial or venous thrombosis [13, 14, 16] . Cervantes et al. reported that 31 (20%) thrombotic events occurred in 18 of 155 IMF patients [2] . Barbui et al. assessed the frequency of major cardiovascular events in 707 patients with IMF; fatal and nonfatal thrombosis occurred in 51 (7.2%) of the patients [3] , although among the IMF patients in the present study the rate was (6.6%) slightly lower. It was reported that arterial events are very common at the time of diagnosis in PV and ET patients, but we observed similar frequencies of arterial and venous events in ET (8% and 10.2%) and PV (8.3% and 6.2%) patients [17] [18] [19] [20] .
In the present study the frequency of FVL mutation was 12.5%, which is (7.4%-10.8) slightly higher than previously reported [6, 7, 10] . The frequency of PT mutation was 4.4% in the present study-2-fold greater than in the general population [5, 8, 9] . While the frequency of these mutations in the present study was higher than previously reported, a relationship between thrombosis, and these mutations in patients with ET, PV, and IMF was not observed. A large retrospective study reported that the frequency of FVL mutation in PV and ET patients was similar to that in the general population and that the mutation was strongly associated with venous thrombotic events prior to and at the time of diagnosis and relapse [11] . Another study reported that there was an increase in the risk of thromboembolic events in patients with ET and PV due to PT mutation [21] . In contrast, some studies reported that there wasn't a significant association between thrombosis and hereditary thrombophilic factors in CMPD patients [12, 13] . Although leukocytosis is a risk factor for thrombosis in patients with PV and ET [19, 20, 22, 23] , the role of hereditary thrombophilic factors for etiology of thrombosis in those disorders remains unclear.
All patients in the present study with hepatic vein thrombosis had FVL mutation carriership, of which 1 also had PT mutation; however, none of patients with portal vein thrombosis had a thrombophilic mutation. FVL and PT mutations were observed in 25 .6%-26.4% and 0%-4.7% of patients with Budd Chiari syndrome, and in 6.06%-7.6% and 0%-3.2% of patients with portal vein thrombosis, respectively [24, 25] . Furthermore, the prevalence of a latent CMPD in patients with hepatic or portal vein thrombosis was estimated to range between 40% and 60% [26, 27] .
In conclusion, even though there wasn't a relationship between thrombosis, and FVL or PT mutation in the present study's patients with ET, PV, and PMF, 3 CMPD patients with hepatic vein thrombosis had FVL mutation. Additional large-scale studies are needed to more clearly determine if all CMPD patients with hepatic vein thrombosis should be investigated for FVL and PT mutation.
